Teva Advances Anti-IL-15 Antibody TEV-’408 to Phase 2b for Vitiligo After Encouraging Phase 1b Readout
Teva Pharmaceutical Industries said it will move its investigational anti-interleukin-15 monoclonal antibody, TEV-’408, into a Phase 2b study for vitiligo in the fourth quarter of 2026. The decision follows results from an open-label Phase 1b trial in adults with active or stable non-segmental vitiligo that reported measurable gains in pigmentation…